# GenEp

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genep

- Industry: Biotechnology
- Headquarters: Charlottesville, US
- Total disclosed funding: $1.4M
- Latest round: Seed (Oct 26, 2021)
- Investors on record: 6

## About

Based in Virginia, US, and founded in 2021 by CEO Andrew Krouse, GenEp, Inc. operates as a pre-clinical stage biotechnology company focuses on creating therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment-resistant epilepsies. In October 2021, GenEp, Inc. raised USD 1.45 million in seed funding co-led by 3B Future Health Fund, Lumira Ventures, and UVA Licensing & Ventures Group, with participation from Kids Connect Charitable Fund, PDI Ventures, and Virginia Innovation Partnership Corporation.

GenEp, Inc. develops selective compounds that modulate sodium channels, Nav1.6 & Nav1.2 gain of function mutations drive uncontrolled seizures and are used in treatment resistance in certain rare genetic epilepsies and other treatment resistant epilepsies. The company offers mouse audiogenic reflex seizure model solutions for human SCN8A epileptic encephalopathy.

## Funding rounds

- Seed, Oct 26, 2021, $1.4M — UVA Licensing & Ventures Group, 3B Future Health Fund, PDI Ventures, Kids Connect Charitable Fund, Virginia Innovation Partnership Corporation, Lumira Ventures

## Investors

- UVA Licensing & Ventures Group (https://capitalatlas.ai/funds/uva-licensing-ventures-group) — Seed
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Seed
- PDI Ventures (https://capitalatlas.ai/funds/pdi-ventures) — Seed
- Kids Connect Charitable Fund — Seed
- Virginia Innovation Partnership Corporation — Seed
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Seed